Angiodynamics (ANGO) Gross Profit (2010 - 2026)

Angiodynamics (ANGO) has reported Gross Profit for 17 consecutive years, with $46.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit rose 10.79% year-over-year to $46.8 million; the trailing twelve-month figure through May 2026 stood at $174.9 million (up 10.9% YoY), and the FY2026 full-year result was $174.9 million, up 10.9% from the prior year.
• Gross Profit improved to $46.8 million in Q2 2026 per ANGO's latest filing, from $41.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $46.8 million in Q2 2026 and bottomed at $35.9 million in Q1 2024.
• Historically, Gross Profit has averaged $41.5 million across 5 years, with a median of $41.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Gross Profit fell 16.92% in 2024, then increased 13.98% in 2025.
• Over 5 years, Gross Profit stood at $45.1 million in 2022, then slipped by 10.68% to $40.3 million in 2023, then declined by 0.88% to $39.9 million in 2024, then gained by 12.22% to $44.8 million in 2025, then advanced by 4.44% to $46.8 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $46.8 million, $41.5 million, and $44.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.